Profile data is unavailable for this security.
About the company
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
- Revenue in USD (TTM)0.00
- Net income in USD-13.03m
- Incorporated2017
- Employees4.00
- LocationAdial Pharmaceuticals Inc1180 SEMINOLE TRAIL, SUITE 495CHARLOTTESVILLE 22901United StatesUSA
- Phone+1 (434) 422-9800
- Fax+1 (302) 655-5049
- Websitehttps://www.adialpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ainos Inc | 40.63k | -16.13m | 6.15m | 46.00 | -- | 0.3409 | -- | 151.47 | -2.77 | -2.77 | 0.0058 | 1.30 | 0.0013 | 0.9734 | 507.88 | 883.26 | -49.47 | -36.36 | -53.53 | -58.33 | -352.82 | 36.82 | -39,708.71 | -813.63 | 1.33 | -30.90 | 0.405 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| GRI Bio Inc | 0.00 | -8.26m | 6.16m | 4.00 | -- | 0.9456 | -- | -- | -54.21 | -54.21 | 0.00 | 0.7287 | 0.00 | -- | -- | 0.00 | -167.58 | -192.93 | -276.80 | -353.99 | -- | -- | -- | -37,650.49 | -- | -- | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| Xenetic Biosciences Inc | 2.52m | -4.08m | 6.19m | 4.00 | -- | 0.8796 | -- | 2.45 | -2.65 | -2.65 | 1.64 | 4.56 | 0.2523 | -- | -- | 630,855.00 | -40.76 | -48.91 | -45.48 | -52.82 | -- | -- | -161.58 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.54m | 6.44m | 2.00 | -- | -- | -- | -- | -0.0117 | -0.0117 | 0.00 | -0.0007 | 0.00 | -- | -- | -- | -89,888.89 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -17.06m | 6.44m | 3.00 | -- | 1.30 | -- | -- | -80.15 | -80.15 | 0.00 | 0.1002 | 0.00 | -- | -- | 0.00 | -350.34 | -132.47 | -2,116.75 | -185.75 | -- | -- | -- | -- | -- | -- | 0.0092 | -- | -- | -- | -23.42 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -13.03m | 6.53m | 4.00 | -- | 1.11 | -- | -- | -4.49 | -4.50 | 0.00 | 0.9185 | 0.00 | -- | -- | 0.00 | -272.04 | -182.35 | -316.95 | -235.45 | -- | -- | -- | -- | -- | -16.22 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -14.93m | 6.56m | 10.00 | -- | 3.97 | -- | -- | -8.49 | -8.49 | 0.00 | 0.0957 | 0.00 | -- | -- | 0.00 | -210.77 | -133.14 | -475.23 | -181.26 | -- | -- | -- | -- | -- | -40.02 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -14.23m | 6.59m | 29.00 | -- | -- | -- | -- | -3.46 | -3.46 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -369.22 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -35.87 | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| NLS Pharmaceutics AG | 0.00 | -6.60m | 6.66m | 3.00 | -- | -- | -- | -- | -6.72 | -6.72 | 0.00 | -9.40 | 0.00 | -- | -- | 0.00 | -380.82 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -27.20 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 6.79m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -6.93m | 6.85m | 16.00 | -- | 2.39 | -- | -- | -2.21 | -2.21 | 0.00 | 0.8829 | 0.00 | -- | -- | 0.00 | -94.60 | -- | -128.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 354.91k | -545.87k | 6.86m | 2.00 | -- | -- | -- | 19.33 | -0.00005 | -0.00005 | 0.00003 | -0.0001 | 8.98 | -- | 15.71 | 177,455.00 | -1,381.60 | -- | -- | -- | 87.28 | -- | -153.81 | -- | -- | -2.16 | -- | -- | -21.46 | -- | 36.92 | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -13.24m | 6.91m | 7.00 | -- | -- | -- | -- | -8.82 | -8.82 | 0.00 | -0.4198 | 0.00 | -- | -- | 0.00 | -198.45 | -87.52 | -594.46 | -116.56 | -- | -- | -- | -- | -- | -128.86 | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 386.00k | -97.82m | 6.98m | 68.00 | -- | -- | -- | 18.07 | -3.03 | -3.03 | 0.0105 | -0.4145 | 0.0033 | -- | -- | 5,676.47 | -84.04 | -54.44 | -111.15 | -64.32 | -- | -- | -25,340.67 | -772.82 | -- | -179.01 | 1.37 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Biora Therapeutics Inc | 892.00k | -35.57m | 7.07m | 58.00 | -- | -- | -- | 7.93 | -12.92 | -11.78 | 0.2163 | -28.99 | 0.0363 | -- | 1.06 | 15,379.31 | -144.59 | -122.84 | -- | -369.01 | -- | -- | -3,988.12 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
Data as of Nov 22 2024. Currency figures normalised to Adial Pharmaceuticals Inc's reporting currency: US Dollar USD
3.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Manchester Capital Management LLCas of 30 Sep 2024 | 48.10k | 0.75% |
| Geode Capital Management LLCas of 30 Sep 2024 | 45.47k | 0.71% |
| Citadel Securities LLCas of 30 Sep 2024 | 33.27k | 0.52% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 27.77k | 0.43% |
| Two Sigma Securities LLCas of 30 Sep 2024 | 27.12k | 0.42% |
| UBS Securities LLCas of 30 Sep 2024 | 4.40k | 0.07% |
| Tower Research Capital LLCas of 30 Sep 2024 | 3.94k | 0.06% |
| 1620 Investment Advisors, Inc.as of 30 Sep 2024 | 3.60k | 0.06% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 300.00 | 0.01% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 52.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
